Repligen Corporation (RGEN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $10.73B
Last updated: Nov 17, 2026 at 11:06 AM ET
Repligen Corporation (RGEN) Earnings: Report Dates and Results
Repligen (RGEN) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Repligen reported EPS of $0.53, above the $0.46 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RGEN has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.2% above the $0.49 reported for the quarter ended Dec 31, 2025.
RGEN Earnings Call
The latest RGEN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RGEN beat 33, missed 4 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $209.31M, up 10.9% from $188.81M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.53 | $0.46 | $0.41 - $0.50 | +15.22% | Beat | +15.2% | 17 | 1 up, 2 down | Oct 27, 2026 | $209.31M |
| Jun 30, 2026 | $0.54 | $0.45 | $0.41 - $0.47 | +20.00% | Beat | +45.9% | 17 | 0 up, 1 down | Jul 28, 2026 | $204.13M |
| Mar 31, 2026 | $0.48 | $0.39 | $0.37 - $0.41 | +23.08% | Beat | +23.1% | 17 | 1 up, 3 down | May 5, 2026 | $194.25M |
| Dec 31, 2025 | $0.49 | $0.44 | $0.42 - $0.50 | +11.52% | Beat | +11.4% | 18 | 1 up, 1 down | Feb 24, 2026 | $197.91M |
| Sep 30, 2025 | $0.46 | $0.41 | $0.39 - $0.45 | +12.20% | Beat | N/A | 18 | 2 up, 2 down | Oct 28, 2025 | $188.81M |
| Jun 30, 2025 | $0.37 | $0.39 | $0.35 - $0.44 | -5.13% | Miss | +12.1% | 18 | 1 up, 2 down | Jul 29, 2025 | $182.37M |
| Mar 31, 2025 | $0.39 | $0.35 | $0.31 - $0.38 | +11.43% | Beat | +39.3% | 17 | 3 up, 1 down | Apr 29, 2025 | $169.17M |
| Dec 31, 2024 | $0.44 | $0.42 | $0.35 - $0.46 | +4.99% | Beat | +33.3% | 15 | 0 up, 0 down | Feb 20, 2025 | $167.55M |
| Sep 30, 2024 | -$0.01 | $0.33 | $0.28 - $0.39 | -103.55% | Miss | -105.1% | 14 | 1 up, 0 down | Nov 12, 2024 | $154.87M |
| Jun 30, 2024 | $0.33 | $0.33 | $0.26 - $0.36 | 0.00% | In line | -37.7% | 13 | 0 up, 0 down | Jul 30, 2024 | $158.84M |
| Mar 31, 2024 | $0.28 | $0.30 | $0.27 - $0.34 | -6.67% | Miss | -56.3% | 12 | 1 up, 0 down | May 1, 2024 | $153.18M |
| Dec 31, 2023 | $0.33 | $0.33 | $0.30 - $0.35 | 0.00% | In line | -51.5% | 11 | 0 up, 0 down | Feb 21, 2024 | $166.62M |
| Sep 30, 2023 | $0.23 | $0.16 | $0.09 - $0.30 | +43.75% | Beat | -70.1% | 13 | 1 up, 2 down | Oct 31, 2023 | $141.19M |
| Jun 30, 2023 | $0.53 | $0.48 | $0.40 - $0.54 | +10.42% | Beat | -41.8% | 13 | 0 up, 1 down | Aug 2, 2023 | $159.17M |
| Mar 31, 2023 | $0.64 | $0.59 | $0.55 - $0.63 | +8.47% | Beat | -30.4% | 12 | 1 up, 0 down | May 2, 2023 | $165.38M |
| Dec 31, 2022 | $0.68 | $0.58 | $0.54 - $0.62 | +17.24% | Beat | -16.0% | 11 | 0 up, 0 down | Feb 22, 2023 | $186.76M |
| Sep 30, 2022 | $0.77 | $0.68 | $0.62 - $0.77 | +13.24% | Beat | -1.3% | 9 | 0 up, 1 down | Nov 1, 2022 | $200.74M |
| Jun 30, 2022 | $0.91 | $0.71 | $0.66 - $0.75 | +28.17% | Beat | +15.2% | 8 | 0 up, 1 down | Aug 2, 2022 | $207.63M |
| Mar 31, 2022 | $0.92 | $0.72 | $0.66 - $0.76 | +27.78% | Beat | +35.3% | 8 | 0 up, 0 down | Apr 27, 2022 | $206.40M |
| Dec 31, 2021 | $0.81 | $0.65 | $0.64 - $0.66 | +24.62% | Beat | +55.8% | 8 | 0 up, 0 down | Feb 17, 2022 | $186.52M |
| Sep 30, 2021 | $0.78 | $0.64 | $0.62 - $0.66 | +21.88% | Beat | +95.0% | 8 | 0 up, 0 down | Oct 28, 2021 | $178.22M |
| Jun 30, 2021 | $0.79 | $0.52 | $0.48 - $0.56 | +51.92% | Beat | +88.1% | 8 | N/A | Jul 27, 2021 | $162.96M |
| Mar 31, 2021 | $0.68 | $0.42 | $0.40 - $0.47 | +61.90% | Beat | +112.5% | 8 | N/A | May 4, 2021 | $142.84M |
| Dec 31, 2020 | $0.52 | $0.31 | $0.29 - $0.32 | +67.74% | Beat | +160.0% | 8 | N/A | Feb 24, 2021 | $108.65M |
| Sep 30, 2020 | $0.40 | $0.28 | $0.26 - $0.31 | +42.86% | Beat | +53.8% | 7 | N/A | Nov 5, 2020 | $94.06M |
| Jun 30, 2020 | $0.42 | $0.28 | $0.24 - $0.31 | +50.00% | Beat | +35.5% | 7 | N/A | Jul 30, 2020 | $87.46M |
| Mar 31, 2020 | $0.32 | $0.21 | $0.13 - $0.23 | +52.38% | Beat | +14.3% | 9 | N/A | May 6, 2020 | $76.09M |
| Dec 31, 2019 | $0.20 | $0.18 | $0.17 - $0.20 | +11.11% | Beat | -4.8% | 9 | N/A | Feb 20, 2020 | $69.47M |
| Sep 30, 2019 | $0.26 | $0.19 | $0.18 - $0.22 | +36.84% | Beat | +30.0% | 8 | N/A | Oct 31, 2019 | $69.44M |
| Jun 30, 2019 | $0.31 | $0.30 | $0.19 - $0.30 | +3.33% | Beat | +93.8% | 5 | N/A | Aug 1, 2019 | $70.69M |
| Mar 31, 2019 | $0.28 | $0.22 | $0.18 - $0.26 | +27.27% | Beat | +64.7% | 7 | N/A | May 9, 2019 | $60.63M |
| Dec 31, 2018 | $0.21 | $0.21 | $0.19 - $0.22 | 0.00% | In line | +5.0% | 8 | N/A | Feb 21, 2019 | $7.14M |
| Sep 30, 2018 | $0.20 | $0.18 | $0.16 - $0.19 | +11.11% | Beat | +33.3% | 9 | N/A | Nov 1, 2018 | $49.53M |
| Jun 30, 2018 | $0.16 | $0.18 | $0.16 - $0.20 | -11.11% | Miss | -20.0% | 9 | N/A | Aug 2, 2018 | $47.73M |
| Mar 31, 2018 | $0.17 | $0.15 | $0.13 - $0.18 | +13.33% | Beat | +13.3% | 9 | N/A | May 8, 2018 | $89.63M |
| Dec 31, 2017 | $0.20 | $0.12 | $0.11 - $0.14 | +66.67% | Beat | +150.0% | 9 | N/A | Feb 22, 2018 | $41.61M |
| Sep 30, 2017 | $0.15 | $0.11 | $0.09 - $0.15 | +36.36% | Beat | +87.5% | 6 | N/A | Nov 9, 2017 | $36.58M |
| Jun 30, 2017 | $0.20 | $0.15 | $0.14 - $0.16 | +33.33% | Beat | +25.0% | 6 | N/A | Aug 3, 2017 | $32.45M |
| Mar 31, 2017 | $0.15 | $0.13 | N/A | +15.38% | Beat | +25.0% | N/A | N/A | May 4, 2017 | $30.59M |
| Dec 31, 2016 | $0.08 | $0.07 | N/A | +14.29% | Beat | +700.0% | N/A | N/A | Feb 22, 2017 | $130.04M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.71, up 64.7% from the year before. It was $0.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.71 | +64.7% |
| Dec 31, 2024 | $1.04 | -40.0% |
| Dec 31, 2023 | $1.73 | -47.3% |
| Dec 31, 2022 | $3.28 | +7.2% |
| Dec 31, 2021 | $3.06 | +84.3% |
| Dec 31, 2020 | $1.66 | +58.1% |
| Dec 31, 2019 | $1.05 | +41.9% |
| Dec 31, 2018 | $0.74 | N/A |
| Dec 31, 2017 | $0.70 | +59.1% |
| Dec 31, 2016 | $0.44 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,824 | 16 | |
| 2026Q2 | Jun 30, 2026 | 8,797 | 16 | |
| 2026Q1 | Mar 31, 2026 | 8,655 | 16 | |
| 2025Q4 | Dec 31, 2025 | 7,978 | 15 | |
| 2025Q3 | Sep 30, 2025 | 7,647 | 17 | |
| 2025Q2 | Jun 30, 2025 | 3,426 | 4 | |
| 2025Q1 | Mar 31, 2025 | 9,427 | 13 | |
| 2024Q4 | Dec 31, 2024 | 7,843 | 15 |
2026Q3 Earnings Call
Opening remarks
Jacob K. Johnson Vice President of Investor Relations Thank you, operator, and good morning, everyone. Welcome to Repligen's 2026 third quarter earnings call. Joining me today are President and Chief Executive Officer Olivier Loeillot, and Chief Financial Officer Jason Garland. Earlier this morning, we issued our earnings release and supplemental presentation, which are available on the Investor Relations section of our website. Before we begin, please note that today's discussion will include forward-looking statements and certain non-GAAP financial measures. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described in today's earnings release and our SEC filings. Reconciliations of non-GAAP to GAAP measures are included in today's earnings release and supplemental materials. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to best reflect the performance of our ongoing operations. With that, I will turn the call over to Olivier Loeillot.
Olivier Loeillot President and Chief Executive Officer Thank you, Jacob. Good morning, everyone, and welcome to our 2026 third quarter call. We had a record quarter with $209 million of revenue. This is a significant milestone as we surpassed our prior peak in the second quarter of 2022. We believe this is another proof point that the industry is poised for its next phase of growth. It also highlights the benefits of our diversified portfolio, and this was driven in part by proteins and chromatography. In addition, we were delighted to close the acquisition of BioLife earlier this month. This combination further expands our capabilities in the rapidly growing cell therapy end market and strengthens our long-term growth platform. We will discuss our initial observations and integration efforts in a moment. But first, we delivered $209 million of revenue in the third quarter, which represented 12.5% organic growth while expanding adjusted operating margins by 170 basis points compared to the prior year. This was an excellent result as we were lapping a very strong quarter in the prior year. Our ability to outpace market growth very significantly this quarter is a testament to our team's strong execution in a market that is still recovering. Following these strong results, incorporating the BioLife acquisition, we are increasing our full-year 2026 guidance. Jason will provide more details. Our updated 2026 guidance includes an expected $24 million revenue contribution from BioLife for the period following its close in our fourth quarter. This assumes BioLife's annual 2026 revenue on a pro forma basis will be approximately $114 million, above the midpoint of BioLife's most recent guidance. The business is performing well, and we are very confident about delivering our deal model for 2027 and beyond.
Frequently Asked Questions About RGEN
When is Repligen's next earnings date?
Repligen's next earnings report is expected for Feb 22, 2027.
Did RGEN beat earnings estimates last quarter?
Yes. Repligen reported EPS of $0.53 for the quarter ended Sep 30, 2026, above the $0.46 estimate, a 15.22% surprise.
What EPS do analysts expect from RGEN next quarter?
The consensus EPS estimate for Repligen for the quarter ending Dec 31, 2026 is $0.53 from 19 analysts, with estimates from $0.49 to $0.57.
How often does RGEN beat earnings estimates?
Repligen beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +11.66%.
RGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts